We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Invites Industry Comment on Ways to Streamline Orphan Drug Designation
FDA Invites Industry Comment on Ways to Streamline Orphan Drug Designation
June 12, 2013
The FDA is seeking industry feedback on ways to minimize the burden on orphan drugmakers seeking designation both stateside and in the EU.